BioSante Pharmaceuticals to Present at BIO 2005 Conference
June 16 2005 - 6:58AM
Business Wire
BioSante Pharmaceuticals (AMEX:BPA) today announced that Stephen M.
Simes, president and chief executive officer, will present a
corporate overview at BIO 2005, the annual international conference
of the Biotechnology Industry Organization. The presentation will
take place on Monday, June 20 at 3:30 p.m. EDT at the Pennsylvania
Convention Center in Philadelphia. For more information on BIO
2005, visit http://www.bio.org/events/2005/. About BioSante
Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone
therapy products to treat both men and women. These hormone therapy
products are gel formulations for transdermal administration that
deliver bioidentical estradiol and testosterone. BioSante's lead
products include Bio-E-Gel(TM) (bioidentical estradiol gel) for the
treatment of women with menopausal symptoms, and LibiGel(TM)
(bioidentical testosterone gel) for the treatment of female sexual
dysfunction (FSD). The current market in the U.S. for estrogen and
testosterone products is approximately $2.5 billion. The company
also is developing its calcium phosphate nanotechnology (CAP) for
novel vaccines, including biodefense vaccines for toxins such as
anthrax and ricin, and drug delivery systems. Additional
information is available online at www.biosantepharma.com. This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. The
statements regarding BioSante contained in this press release that
are not historical in nature, particularly those that utilize
terminology such as "may," "will," "should," "likely," "expects,"
"anticipates," "estimates," "believes" or "plans," or comparable
terminology, are forward-looking statements. Forward-looking
statements are based on current expectations and assumptions, and
entail various risks and uncertainties that could cause actual
results to differ materially from those expressed in such
forward-looking statements. Important factors known to BioSante
that cause actual results to differ materially from those expressed
in such forward-looking statements are the difficulty of developing
pharmaceutical products, obtaining regulatory and other approvals
and achieving market acceptance, and other factors identified and
discussed from time to time in BioSante's filings with the
Securities and Exchange Commission, including those factors
discussed on pages 19 to 31 of BioSante's Form 10-KSB, which
discussion also is incorporated herein by reference.
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Biosante Pharmaceuticals (American Stock Exchange): 0 recent articles
More BioSante Pharmaceuticals, Inc. News Articles